In Vitro Drug Sensitivity of Acute Myeloid Leukemic Cells Using the Methyl-Thazol-Tetrazolium Assay

  • A. Mestice
  • G. Specchia
  • M. R. Coppi
  • I. Attolico
  • A. Ricco
  • D. Pastore
  • A. Vaira
  • M. R. de Paolis
  • V. Caretto
  • V. Liso
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 38)

Abstract

Different assays (clonogenic, dye exclusion, etc.) have been developed to assess the chemosensitivity of malignant cells. The MTT assay, in particular, based on the reduction by living cells of MTT [3-4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) to a formazan product, provides a simple, automated, and efficient method for chemosensitivity testing in leukemias. In this study, in vitro drug sensitivity was assessed in the cells from 46 adult acute myeloid leukemias (AML). Dose-response curves were obtained for cytosine arabinoside (ara-C), daunorubicin (DNR), idarubicin (IDA), mitoxantrone (MIT), etoposide (VP-16). There were marked interindividual differences in leukemic cell survival (LCS) values (expressed as the percentage of cell survival with respect to the untreated controls). LCS was less than 50% in 30/46 samples (65%) tested with ara-C, in 38/41 (98%) with IDA, in 41/42 (98%) with DNR, in 40/46 (87%) with MIT, and in 30/45 (67%) with VP-16. The in vitro results were compared with the clinical response in 31 patients treated by combination chemotherapy according to GIMEMA protocols (AML 10 and P 491). The MTT test correlated with in vivo response in 18 (58%) out of 31 patients. Sensitive chemotherapeutic response in vitro but resistance in vivo was observed in 12 patients. Only one AML patient was found to be resistant in vitro and sensitive in vivo. Our preliminary results suggest that the MTT assay may be useful in evaluating chemosensitivity in some AML patients, although further studies are needed to assess the clinical utility of in vitro chemosensitivity tests.

Keywords

Leukemia Etoposide Diphenyl Tetrazolium Spectrophotometry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weisenthal LM, Lippman ME (1985) Clonogenic and non-clonogenic in vitro chemosensitivity assay. Cane Treat Rep 69: 616–32Google Scholar
  2. 2.
    Karney DN, Winkler CF (1985) In vitro assays of chemotherapeutic sensitivity. In: Important advances in oncology. De Vita et al (eds). p.78 JB Lippincott: PhiladelphiaGoogle Scholar
  3. 3.
    Marie JP (1987) Prognostic value of clonogenic assay for induction for duration of complete remission in acute myelogenous. Leukemia 1: 121PubMedGoogle Scholar
  4. 4.
    Weisenthal LM, Marsden JA, Dill PL, Macaluso CK (1983) A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cane Res 43: 749–57Google Scholar
  5. 5.
    Bird MC, Bosanquet AG, Gilby ED (1985) In vitro determination of tumor sensitivity in haematological malignancies. Haematol Oncol 3:1–9CrossRefGoogle Scholar
  6. 6.
    Berridge MV, An S. Tan. (1993) Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): Subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303: 474–82PubMedCrossRefGoogle Scholar
  7. 7.
    Mossmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Imm Meth 65: 55CrossRefGoogle Scholar
  8. 8.
    Pieters R, Huisman DR, Leyva A, Veerman AJP (1988) Adaptation of a rapid tetrazolium based (MTT-) assay for chemosensitivity testing in childhood leukaemia. Cancer Lett 41: 323PubMedCrossRefGoogle Scholar
  9. 9.
    Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T et al. (1992) Intensive consolidation chemotheraphy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission: an EORTC/GIMEMA phase III trial (AML 8B). Leukemia 6: Suppl 2: 120–3Google Scholar
  10. 10.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galtan DAG, Gralnik HR, Sultan G (1976) Proposal for the classification of the acute leukemias. Br J Haematol 33: 451–58PubMedCrossRefGoogle Scholar
  11. 11.
    Pieters R, Huismans DR, Leiva A, Veerman AJP (1989) Comparison of the rapid automated MTT assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia. Br J Cancer 59:217–20PubMedCrossRefGoogle Scholar
  12. 12.
    Kaspers GJL, Kardos G, Pieters R, van Zantwijk CH, Klumper E, Hahlem K, de Waal FC, van Wering ER, Veerman AJP (1994) In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia 8: 24–29PubMedGoogle Scholar
  13. 13.
    Colton T (1974) Statistics in medicine. Little, Brown, BostonGoogle Scholar
  14. 14.
    Bird MC, Forskit S, Gilby ED, Bosanquet AG (1986) The influence of sample source and cell concentration of in vitro chemosensitivity of haematological tumors. Br. J.Cancer 53: 539PubMedCrossRefGoogle Scholar
  15. 15.
    Sargent JM, Taylor CG (1989) Appraisel of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukemia. Br.J Cancer 60: 206–10PubMedCrossRefGoogle Scholar
  16. 16.
    Hwang W, Chen L, Huang S, Wang C, Tseng MT (1993) Prediction of chemotherapy response in human leukemia using in vitro chemosensitivity. Luek Res 17: 685–88CrossRefGoogle Scholar
  17. 17.
    Bird MC, Bosanquey AG, Forskit S, Gilby ED (1988) Long term comparison of results of an in vitro drug sensitivity assay with patient response in lymphatic neoplasm. Cancer 61: 1104–9PubMedCrossRefGoogle Scholar
  18. 18.
    Weisenthal LM, Dill PL, Finkelstein JZ, Duarte TE, Baker JA, Moran EN (1976) Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasm. Cancer Treat Rep 70: 1283–88Google Scholar
  19. 19.
    Boekhorst PAW, Lowenberg B, Sonneveld P (1993) Enhance chemosensitivity acute myeloid leukemia by hematopoietic growth factors: a comparison of the MTT assay with a clonogenic assay. Leukemia 7:1637–44Google Scholar
  20. 20.
    Kirkpatrick DL, Duke M, Goh TS (1990) Chemosensitivity testing of fresh human leukemiacells using both a dye-exclusion assay and a tetrazolium dye (MTT) assay. Leukemia Res 14: 459–66CrossRefGoogle Scholar
  21. 21.
    Larsonn R, Nygren P (1989) A semi-automated fluorometric method for determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res 9: 1111–20Google Scholar
  22. 22.
    Larsonn R, Jorgen K, Sandberg C, Nygren P (1992) Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorimetric microculture assay (FMCA). Int J Cancer 50: 177–85CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • A. Mestice
    • 1
  • G. Specchia
    • 1
  • M. R. Coppi
    • 1
  • I. Attolico
    • 1
  • A. Ricco
    • 1
  • D. Pastore
    • 1
  • A. Vaira
    • 1
  • M. R. de Paolis
    • 1
  • V. Caretto
    • 1
  • V. Liso
    • 1
  1. 1.Hematology ServiceUniversity of BariBariItaly

Personalised recommendations